TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6828256

Group type: EXPERIMENTAL
Intervention: Aqueous suspension of cofosfolactamines
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tablets of cofosfolactamines
Number of subjects: 5
Study: 29850450

Group type: EXPERIMENTAL
Intervention: Olive oil group (receiving 20% of total daily energy from olive oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (normal consumption of oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between olive oil group and control group
Number of subjects: 50
Study: 27267431

Group type: EXPERIMENTAL
Intervention: Lispro administered by QS-M needle-free jet injector
Number of subjects: 18
Study: 24598007

Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal aerosol (CIC-HFA) 74-μg (37 μg/spray, 1 spray/each nostril)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mometasone furoate monohydrate aqueous nasal spray (MFNS) 200-μg (50 μg/spray, 2 sprays/each nostril)
Number of subjects: 14
Study: 22374626

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (cognitive therapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Systematic desensitization (behavioral therapy)
Number of subjects: 50
Study: 21046771

Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide and Pingyangmycin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pingyangmycin only
Number of subjects: 29
Study: 18323413

Group type: EXPERIMENTAL
Intervention: Total estradiol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Free estradiol
Number of subjects: 153

Group type: COMPARATOR
Intervention: Total estradiol concentration comparison
Number of subjects: 153

Group type: COMPARATOR
Intervention: Testosterone and sex hormone binding globulin
Number of subjects: 153
Study: 16555489

Group type: EXPERIMENTAL
Intervention: Checklist-based tool for evaluating protocol quality
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 11818522

Group type: COMPARATOR
Intervention: Low fatty acid amide hydrolase (FAAH) activity in lymphocytes of IVF-embryo transfer patients who failed to achieve an ongoing pregnancy (46 +/- 17 pmol/min per mg protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased blood anandamide (AEA) levels in patients who failed to achieve an ongoing pregnancy (4.0 +/- 2.2 pmol/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No difference in blood levels of 2-arachidonoylglycerol or N-palmitoylethanolamine between pregnant and nonpregnant women
Number of subjects: 0

Group type: COMPARATOR
Intervention: No difference in the activity of the AEA membrane transporter or amounts of cannabinoid receptors in lymphocytes between groups
Number of subjects: 0
Study: 10608579

Group type: EXPERIMENTAL
Intervention: Low concordance status (<50%)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Low concordance group
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Concordance between parents and youth
Number of subjects: 333
Study: 7782055

Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 8
Study: 2117147

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 7032697

Group type: EXPERIMENTAL
Intervention: acebutolol (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: nifedipine (N)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: association of acebutolol and nifedipine (A+N)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 16
Study: 31711499

Group type: EXPERIMENTAL
Intervention: SLIMMER lifestyle intervention
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 316
Study: 28679476

Group type: EXPERIMENTAL
Intervention: Percutaneous autologous bone marrow aspirate instillation at fracture site along with cannulated cancellous screw fixation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Closed reduction and cannulated cancellous screw fixation (control)
Number of subjects: 32
Study: 26204331

Group type: EXPERIMENTAL
Intervention: Low-dose olprinone continuously infused for 24 hours starting just before anesthesia induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo continuously infused for 24 hours starting just before anesthesia induction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose olprinone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23709289

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (3 mg/kg) before passive heat loading (PHL)
Number of subjects: 9
Study: 21251076

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.5%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 29
Study: 19766056

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 8
Study: 24683674

Group type: EXPERIMENTAL
Intervention: Daily Sprinkles (12.5 mg of elemental iron, n = 79)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Once weekly Sprinkles (30 mg of elemental iron, n = 73)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 136
Study: 15342807

Group type: EXPERIMENTAL
Intervention: Recombinant human leptin treatment for up to three months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant human leptin treatment
Number of subjects: 14
Study: 11253161

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 10759276

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 71

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 71
Study: 9200286

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.25 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PYY (0.25 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.5 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PYY (0.5 pmol/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 and PYY combined (0.25 pmol/kg/min each)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 and PYY combined (0.5 pmol/kg/min each)
Number of subjects: 8
Study: 1338742

Group type: EXPERIMENTAL
Intervention: Live enterovirus oral vaccines, administered in 2-3 doses at intervals of 7-10 days.
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Nonimmunized subjects (control group).
Number of subjects: 150000
Study: 4014743

Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 2 or more mg of morphine
Number of subjects: 139

Group type: COMPARATOR
Intervention: 0 mg morphine (control)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 3 mg morphine
Number of subjects: 139
Study: 31199765

Group type: EXPERIMENTAL
Intervention: Fresh coconut (100 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Groundnut and groundnut oil
Number of subjects: 0
Study: 29516702

Group type: EXPERIMENTAL
Intervention: Balance acupuncture combined with motor relearning training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine acupuncture combined with motor relearning training
Number of subjects: 62
Study: 26865472

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 5 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 10 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 20 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intravenous buprenorphine infusion
Number of subjects: 3
Study: 24828298

Group type: EXPERIMENTAL
Intervention: PUVAsol + isotretinoin (0.5 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PUVAsol only (control group)
Number of subjects: 40
Study: 22031045

Group type: EXPERIMENTAL
Intervention: High-fidelity simulator (HFS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-fidelity simulator (LFS)
Number of subjects: 16
Study: 20538183

Group type: EXPERIMENTAL
Intervention: Short-Term Life Review interview
Number of subjects: 68
Study: 18588452

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study: 15921865

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.625/2.5 mg daily for 24 weeks
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.45/1.5 mg daily for 24 weeks
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.3/1.5 mg daily for 24 weeks
Number of subjects: 1028
Study: 11938636

Group type: EXPERIMENTAL
Intervention: Sterioss (test group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sterioss (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Southern Implants (test group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Southern Implants (control group)
Number of subjects: 48
Study: 10190531

Group type: EXPERIMENTAL
Intervention: Nicorandil therapy for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8544891

Group type: EXPERIMENTAL
Intervention: Laboratory tests ordered by multiple physicians
Number of subjects: 1500
Study: 2253292

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 10-15 micrograms.kg-1 (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1 (Group II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 105
Study: 30993861

Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: metformin 1000-1500 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 0
Study: 27990626

Group type: EXPERIMENTAL
Intervention: Banking Time
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Child time
Number of subjects: 470

Group type: COMPARATOR
Intervention: Business as usual (BAU)
Number of subjects: 470
Study: 25588587

Group type: EXPERIMENTAL
Intervention: Intravenous high single-dose of iron isomaltoside 1000 (1,200 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 200
Study: 24114290

Group type: EXPERIMENTAL
Intervention: 0.25% topical sodium lauryl sulfate (SLS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.5% topical sodium lauryl sulfate (SLS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1% topical sodium lauryl sulfate (SLS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2% topical sodium lauryl sulfate (SLS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry (LDF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study: 21301830

Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unipolar hemiarthroplasty
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetabular erosion
Number of subjects: 120
Study: 19132712

Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 mg/day for 3 days, 20 mg/day for 3 days, then 30 mg/day for 8 days)
Number of subjects: 18
Study: 17143605

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1160
Study: 15220020

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 5/325 mg
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 11521984

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 563

Group type: COMPARATOR
Intervention: Cisapride 10 mg bid for 4 weeks
Number of subjects: 563
Study: 9630109

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: N-terminal proANF
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Heart rate changes
Number of subjects: 216
Study: 8140872

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2842206

Group type: EXPERIMENTAL
Intervention: nedocromil sodium (4 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 31712421

Group type: EXPERIMENTAL
Intervention: suvorexant (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: brotizolam (0.25 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: brotizolam
Number of subjects: 30
Study: 28407408

Group type: EXPERIMENTAL
Intervention: High-stress parenting group (n=785) with adult children having disabilities
Number of subjects: 5628

Group type: COMPARATOR
Intervention: Low-stress parenting group (n=4843) with adult children being healthy
Number of subjects: 5628
Study: 25980923

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of platelet-rich plasma (PRP)
Number of subjects: 57
Study: 23337558

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (6 treatments over 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (answered HIT-6 questionnaire twice before receiving treatment)
Number of subjects: 20
Study: 21622496

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (measured in UK units, 8 g of ethanol) in quitters
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (measured in UK units, 8 g of ethanol) in smokers
Number of subjects: 698
Study: 18971524

Group type: EXPERIMENTAL
Intervention: Top decile group (orthostatic BP increase >7.8 mmHg)
Number of subjects: 605
Study: 17116022

Group type: EXPERIMENTAL
Intervention: RWJ-333369 alone (5 days 250 mg q12h; 5 days 500 mg q12h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) alone (3 days 100 mg q12h; 3 days 200 mg q12h; 22 days 300 mg q12h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of CBZ (300 mg q12h) and RWJ-333369 (5 days 250 mg q12h; 5 days 500 mg q12h)
Number of subjects: 24
Study: 12894480

Group type: EXPERIMENTAL
Intervention: Nikavir
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 11099873

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (ERT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 9255651

Group type: EXPERIMENTAL
Intervention: Intermittent furosemide administration
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continuous furosemide infusion
Number of subjects: 46
Study: 3919832

Group type: EXPERIMENTAL
Intervention: Stop drinking coffee altogether
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Stop drinking coffee for five weeks, then drink boiled coffee
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Stop drinking coffee for five weeks, then drink filter coffee
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continue with usual coffee intake
Number of subjects: 33
Study: 25755259

Group type: EXPERIMENTAL
Intervention: Family CBT (FCBT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Child CBT (CCBT)
Number of subjects: 123
Study: 28848766

Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year with adherence ≥70%
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study: 26481739

Group type: EXPERIMENTAL
Intervention: Intravaginal 25-μg misoprostol
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 23880883

Group type: EXPERIMENTAL
Intervention: Tio plus SFC (18 μg once daily + 50/250 μg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tio (18 μg once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SM (50 μg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SFC (50/250 μg twice daily)
Number of subjects: 60
Study: 21681869

Group type: EXPERIMENTAL
Intervention: Association Splitting (AS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 46
Study: 17522609

Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg/day)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Combined iron and zinc supplementation (50 mg/day iron and 14 mg/day zinc)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Zinc supplementation (14 mg/day)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Iron-only supplementation
Number of subjects: 821
Study: 16813912

Group type: EXPERIMENTAL
Intervention: Q-tip test
Number of subjects: 43

Group type: COMPARATOR
Intervention: Voiding cystourethrogram
Number of subjects: 43
Study: 15070888

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 micro g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 micro g)
Number of subjects: 80
Study: 11254789

Group type: EXPERIMENTAL
Intervention: Naltrexone (5 mg/kg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 10
Study: 9038032

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 37
Study: 8508009

Group type: EXPERIMENTAL
Intervention: Garlic powder (daily dose, 800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3494917

Group type: EXPERIMENTAL
Intervention: Cardiologic and Type A behavior counseling
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Cardiologic counseling only
Number of subjects: 1012

Group type: COMPARATOR
Intervention: No group counseling
Number of subjects: 1012
Study: 30021690

Group type: COMPARATOR
Intervention: Orlistat 60-mg capsule
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Orlistat 48-mg tablet
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Orlistat 144-mg tablet
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Orlistat 24-mg tablet
Number of subjects: 83
Study: 27103095

Group type: EXPERIMENTAL
Intervention: Transurethral removal using nephroscope (Group 2)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Transurethral removal using cystoscope (Group 1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Percutaneous cystolithotripsy (PCCL) (Group 3)
Number of subjects: 210

Group type: COMPARATOR
Intervention: All three techniques
Number of subjects: 210

Group type: COMPARATOR
Intervention: All three groups
Number of subjects: 210
Study: 24728578

Group type: EXPERIMENTAL
Intervention: CP-CEF (carboplatin and weekly paclitaxel followed by CEF)
Number of subjects: 181

Group type: COMPARATOR
Intervention: P-CEF (weekly paclitaxel followed by CEF)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CP-CEF (in triple-negative breast cancer)
Number of subjects: 181

Group type: COMPARATOR
Intervention: P-CEF (in triple-negative breast cancer)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CP-CEF
Number of subjects: 181

Group type: COMPARATOR
Intervention: P-CEF
Number of subjects: 181
Study: 22242619

Group type: EXPERIMENTAL
Intervention: Mentoring in addition to treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: More mentoring with fewer treatment sessions
Number of subjects: 90
Study: 20185595

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 18362420

Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (without PICSO)
Number of subjects: 34
Study: 15701489

Group type: EXPERIMENTAL
Intervention: Role-play group (1-hour lecture plus 1-hour role-playing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) group (1-hour EBM journal club)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Role-play group
Number of subjects: 16

Group type: COMPARATOR
Intervention: EBM group
Number of subjects: 16
Study: 11340102

Group type: EXPERIMENTAL
Intervention: Garlic oil (GO) 8.2 mg/d (allyl sulfides) for 11 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Garlic powder (GP) 7.8 mg allicin/d for 11 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo for 11 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Garlic oil (GO)
Number of subjects: 51
Study: 9473976

Group type: EXPERIMENTAL
Intervention: Hand motion direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motion completion time
Number of subjects: 0
Study: 7940135

Group type: EXPERIMENTAL
Intervention: Increased inspiratory carbon dioxide concentrations (95% O2; 5% CO2; endtidal CO2 approx. 6.5%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 15
Study: 2481163

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Metoprolol
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients already on a beta-blocker)
Number of subjects: 515
Study: 28760693

Group type: EXPERIMENTAL
Intervention: Taping with tension
Number of subjects: 23

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 23
Study: 27237598

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (TNP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 82